CHR HANSEN HLDG A/S SPONSORED ADR DENMA (OTCMKTS:CHYHY) Sellers Increased Their Shorts By 32.05%

Chr. Hansen Holding A/S (OTCMKTS:CHYHY) Corporate Logo

CHR HANSEN HLDG A/S SPONSORED ADR DENMA (OTCMKTS:CHYHY) recorded an increase of 32.05% in shorted shares. In January was published CHYHY’s total 10,300 shorted shares by FINRA. The up change of 32.05% from 7,800 shares was reported. CHR HANSEN HLDG A/S SPONSORED ADR DENMA (OTCMKTS:CHYHY) has 43,900 shares average volume. It’ll cost 0 days for CHYHY to recover its previous position.

CHYHY is hitting $47.68 during the last trading session, after decreased 0.93%.Currently Chr. Hansen Holding A/S is after 0.00% change in last January 14, 2018. CHYHY has also shares volume. CHYHY by 0.00% the S&P 500.

Chr. Hansen Holding A/S, a bioscience company, develops and sells natural solutions for the food, nutritional, pharmaceutical, and agricultural industries.The firm is worth $12.54 billion. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, color, texture, safety, preservation, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry.The P/E ratio is 47.33. The Health & Nutrition segment produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula, animal feed, and plant protection industries.

More recent Chr. Hansen Holding A/S (OTCMKTS:CHYHY) news were brought out by Seekingalpha.com, Seekingalpha.com and Seekingalpha.com. The first one has “CHR Hansen Holding A/S ADR 2018 Q3 – Results – Earnings Call Slides – Seeking Alpha” as a title and was brought out on June 28, 2018. The next is “CHR Hansen Is A Rare Story In The Food Sector – Seeking Alpha” on September 15, 2015. And last was brought out on June 20, 2016, called “Enzyme Leader Novozymes: Biotech Without Biotech Risk – Seeking Alpha”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.